Is approving esketamine as an antidepressant for treatment resistant depression associated with recreational use and risk perception of ketamine? Results from a longitudinal and cross-sectional survey in nightlife attendees

Grabski M, Waldron J, Freeman TP, van Laar M, Curran HV. International journal on drug policy 2022; 102:e103612

ARTICLE IDENTIFIERS

DOI: 10.1016/j.drugpo.2022.103612 PMID: 35151083 PMCID: not available

JOURNAL IDENTIFIERS

LCCN: not available pISSN: 0955-3959 eISSN: 1873-4758 OCLC ID: 22592772 CONS ID: not available US National Library of Medicine ID: 9014759

This article was identified from a query of the SafetyLit database.